natgillin/translations-raw huggingface dataset:
A further embodiment of the invention is an above compound of formula 1 for use as a medicament for the treatment of asthma and allergic diseases, gastrointestinal inflammatory diseases, glomerulonephritis, eosinophilic diseases, chronic obstructive pulmonary disease, infection by pathogenic microbes and rheumatoid arthritis. 
Spoj formule 1 u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time, da se upotrebljava kao lijek za liječenje astme i alergijskih bolesti, gastrointestinalnih upalnih bolesti, glomerulonefritisa, eozinofilnih bolesti, kronične opstrukcijske plućne bolesti, infekcije putem patogenih mikroba i reumatoidnog artritisa.
Set rate function. 
Funkcija podešavanja brzine.
Process according to claim 8, said process comprising reacting aminodesacetoxy cephalosporanic acid (7-ADCA) with D-dihydrophenylglycine in activated form (DHa) in the presence of an enzyme in a reaction mixture to form cephradine and crystallizing the cephradine from an aqueous solution, in which aqueous solution the ratio mCEF/(m7-ADCA + mCEF) > 0.7 and wherein xDH = 0-2 wt.%, wherein mCEF = molar quantity of cephradine in the aqueous solution; m7-ADCA = molar quantity of 7-ADCA in the aqueous solution; and xDH = concentration of DH in the aqueous solution relative to the total weight of the aqueous solution. 
Postupak prema zahtjevu 8, naznačen time da navedeni postupak sadrži reakciju 7-aminodeacetoksi cefalosporanske kiseline (7-ADCA) s D-dihidrofenilglicinom u aktiviranom obliku (DHa) u prisutnosti enzima u reakcijskoj smjesi da nastane cefradin i kristaliziranje cefradina iz vodene otopine, u kojoj je omjer vodene otopine Mcrr/(mMyapcaA + Mcrr) > 0.7 1 pri čemu Xpg = 0-2 mas.%, pri čemu mcrr = molarna količina cefradina u vodenoj otopini; m;apca = molarna količina 7-ADCA u vodenoj otopini; i Xpg = koncentracija DH u vodenoj otopini u odnosu na ukupnu masu vodene otopine.
As previously indicated, the present invention relates to an ultra-fast setting cement composition comprising at least amorphous calcium aluminate comprising by weight, as compared to amorphous calcium aluminate total weight: 
HR P20181382 T1 PATENTNI ZAHTJEVI Ultrabrzo vežuća cementna smjesa koja u najmanju ruku sadrži amorfni kalcijev aluminat, koji sadrži, težinski, u usporedbi s ukupnom težinom amorfnog kalcijevog aluminata:
An anti-IL-1B antibody or IL-1B-binding fragment thereof for use of claims 1-5, wherein administration of an initial dose of the antibody or antibody fragment is followed by the administration of one or more subsequent doses, and wherein at least one of the subsequent doses is in an amount that is more than the initial dose. 
Anti-IL-1B protutijelo ili njegov IL-1B-vezujući fragment za uporabu prema zahtjevima 1-5, gdje nakon primjene početne doze protutijela ili fragmenta protutijela slijedi primjena jedne ili više sljedećih doza, i gdje je barem jedna od tih sljedećih doza u količini većoj od početne doze.
Composition according to claim 1, wherein at least a portion of the coated particles further comprises a release modifying coating layer which is placed between the complex and the bioadhesive layer and comprises at least one release modifying material. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time,da barem dio od obloženih čestica dodatno obuhvaća obložni sloj za modificiranje oslobađanja, koji je smješten između kompleksa i bioljepljivog materijala te obuhvaća najmanje jedan materijal koji modificira oslobađanje.
(b3) an acrylic compound selected from the group consisting of Isobutyl acrylate, isopentyl acrylate, pentyl acrylate, N-isopropyl acrylamide and butyl acrylate, preferably butyl acrylate; 
(b3) akrilnog spoja, izdvojenog 1z grupe, koju čine izobutil akrilat, izopentil akrilat, pentil akrilat, N-izopropil akrilamid i butil akrilat, prvenstveno butil akrilat;
wherein the antibody is a bispecific antibody. The antibody of claim 1, further comprising at least one, two, or three HC framework regions (FRs) selected from: 
Polinukleotid prema zahtjevu 1 (i), naznačen time, da monoklonalno protutijelo nadalje obuhvaća najmanje jedno, dva ili tri HC-okvirna područja (FR) odabrana od sljedećih:
The portable mat as in claim 1, wherein the base (120) is defined by and bounded by only two straight edges (102a, 102d) intersecting orthogonally and curved edges (102b, 102c) with straight portions joining the two straight edges. 
Prenosivi podložak prema patentnom zahtjevu 1, naznačen time, da je osnova (120) određena i omeđena samo s dva ravna ruba (102a, 102d) koji se sijeku pod pravim kutem i sa zakrivljenim rubovima (102b, 102c), čiji se ravni dijelovi spajaju s dva ravna ruba.
Thus, depending on the need, frame (200) can be bent or flexed when required. The frame (200) can also comprise at least one wing shield (210) preventing the sprayed liquid from being affected by wind. 
Rashladni sustav priključen na ulazni otvor za zrak hladnjaka (100), s - najmanje jednim okvirom (200), - najmanje jednom komponentom (240) raspršivanja tekućine smještenom na spomenutom okviru (200),
Use of a compound according to claim 1, for the preparation of a medicament useful in the treatment of disorders due the inhibition of casein kinase Ie activity. 
Upotreba spoja u skladu s patentnim zahtjevom 1, namijenjena pripravi medikamenta korisnog u liječenju poremećaja inhibiranjem aktivnosti kazein-kinaze Ig.
(R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl] -2-propylpentyl phosphoric acid monoester, or a pharmaceutically acceptable salt or hydrate thereof. 
(R)-2-amino-5-[2-klor-4-(3-trifluormetilfenilthio)fenil]-2-propilpentilni monoester fosforne kiseline, ili njihove farmaceutski prihvatljive soli ili hidrati.
The method as claimed in claim 1, wherein the product to be ground is selected from the group consisting of coffee, barley, malt, ginseng, and tea. 
Postupak sukladno jednom ili više prethodnih zahtjeva, pri čemu je proizvod koji će biti samljeven odabran iz skupine koja obuhvaća kavu, ječam, slad, ginseng, čaj, infuzije i ostale druge prehrambene proizvode koje je moguće zakuhati.
A molecule comprising an antibody Fab fragment that specifically binds human AB peptide, wherein the antibody fragment comprises a light chain variable region of SEQ ID NO: 1 and a heavy chain variable region of SEQ ID NO: 2, and wherein said antibody fragment is covalently attached to a polyethylene glycol molecule at the cysteine at amino acid 56 of SEQ ID NO: 2, wherein the polyethylene glycol molecule has a molecular weight of 0.5 kD to 30 kD. 
PATENTNI ZAHTJEVI Molekula, naznačena time što sadrži Fab fragment protutijela koji se specifično veže na ljudski peptid Af između aminokiselina na položajima 13 do 28, gdje fragment protutijela sadrži varijabilno područje lakog lanca sa SEQ ID NO: 11 varijabilno područje teškog lanca sa SEQ ID NO: 2, te gdje navedeni Fab fragment protutijela je kovalentno vezan na 20 kD veliku molekulu polietilen-glikola na cisteinu na aminokiselinskom položaju 56 u SEQ ID NO: 2.
Composition according to claim 3, comprising cytisine having particle size d90 below 80 µm. 
Sastav prema zahtjevu 2, obuhvaćajući citizin koji ima veličinu čestice dgg ispod 80 um.
determining (56) said operational parameters from said matched estimated torque-speed transfer function and said computed torque-speed transfer function. 
- određivanja (56) navedenih radnih parametara iz navedene uspoređene procijenjene funkcije prijenosa okretnog momenta u brzinu i navedene izračunate funkcije prijenosa okretnog momenta u brzinu.
X is selected from O and S. 
X se bira između 0 1 S.
reacting the compound of formula (6) or a salt thereof with a disulfide compound to form a compound of formula (3), or a salt thereof, 
reakciju spoja formule (IV) s N-hidroksisukcinimidom u prisutnosti EDC-a, da se dobije spoj s formulom (V).
In one embodiment, the persisting population of genetically engineered T cells comprises at least one cell selected from the group consisting of a T cell that was administered to the human, a progeny of a T cell that was administered to the human, and a combination thereof. 
T stanica za upotrebu prema patentnom zahtjevu 7, naznačena time što perzistentna populacija genetski modificiranih T stanica sadrži najmanje jednu stanicu odabranu iz grupe koja se sastoji od T stanice koja je bila primjenjena kod čovjeka, potomstva T stanice koja je bila primjenjena kod čovjeka, i njihove kombinacije.
The results of the studies are set out below in Tables A, B, C, D and E. 
Rezultati proučavanja su prikazani dolje u Tabelama A, B, C,D i E.
An apparatus for estimating the fraction of fetal DNA in DNA obtained from a bodily fluid of a pregnant individual, the apparatus comprising: 
Postupak procjene frakcije fetalne DNK u DNK dobivenoj iz tjelesne tekućine trudne osobe, te postupak sadrži:
The method of claim 1, wherein the psicose-epimerase isolated from Agrobacterium tumefaciens has the amino acid sequence of SEQ ID NO: 1. 
Postupak prema zahtjevu 1, naznačen time da psikoza-epimeraza koja je dobivena iz Agrobacterium tumefaciens ima sekvencu amino kiselina iz SEQ ID NO: 1.
The composition of any preceding claim, wherein the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:1, 2, 3, 4, 5, 6, or 9, preferably wherein the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:9, more preferably wherein the bacterial strain has the 16s rRNA sequence represented by SEQ ID NO:9, more preferably wherein the bacterial strain is of the Parabacteroides distasonis strain deposited under accession number NCIMB 42382. 
Sastav za upotrebu prema bilo kojem od patentnih zahtjeva 1-6, pri čemu soj bakterija sadrži 16s rRNK sekvenciju koja je najmanje 98%, 99%, 99,5% ili 99,9% jednaka SEQ ID NO: 1, 2, 3, 4, 5, 6 ili 9, pri čemu je poželjno da soj bakterija sadrži 16s rRNK sekvenciju koja je najmanje 98%, 99%, 99,5% ili 99,9% jednaka SEQ ID NO: 9 ili pri čemu soj bakterija sadrži 16s rRNK sekvenciju koja je predstavljena kao SEQ ID NO: 9.
contacting a peptide consisting of the candidate sequence selected in step (ii) with an antigen presenting cell; 
(ili) stavljanja u kontakt peptida koji ima slijed kandidat nabrojan u koraku (ii) sa stanicom za predočavanje antigena;
A method for removal of fragments from containers, on automatic production lines, wherein said containers are conveyed on a conveying line, comprising the steps of: changing, i.e. reducing or eliminating, the electrostatic force between said fragments and the inner surface of said containers, and 
promjene smanjenjem ili uklanjanjem elektrostatske sile između navedenih komadića stakla (30) i unutrašnje površine (5b) navedenih staklenih cijevi ili spremnika izrađenih od staklenih cijevi korištenjem sredstava za mijenjanje elektrostatske sile (40)
comprising a reductive amination reaction between a compound of following formula (VIII): where R1, R2 and R3 are as defined in claim 1, and a compound of following formula (XI): 
(VIII) gdje R1, R2 i R3 jesu kao što je definirano u patentnom zahtjevu 1, i spoja sljedeće formule (XI):
The compound was prepared from the cyano intermediate from Step A using a similar procedure described in Example 9.8, Step B. 
Spoj je pripremljen iz cijano intermedijera iz koraka A uporabom postupka sličnog onome opisanome u Primjeru 9.8, korak B.
Conveniently, the edge of each spoke is shaped to allow the drive tooth to pass over it when the actuator is pivoted from its open into its closed position. 
Inhalator prema zahtjevu 33, gdje je rub svake prečke (91) oblikovan tako da omogući pogonskom zupčaniku (102) da prođe preko njega kada je aktivator (72) pomaknut iz svojeg otvorenog u zatvoreni položaj.
Method according to any one of the preceding claims, characterized in that following the addition of said 2-((1-methylpropyl)amino)ethanol, the suspension conductivity does not change by more than 10 %, preferably does not change by more than 6 %, and more preferably does not change by more than 3 %. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da se nakon dodavanja navedenog 2-((1-metilpropiljaminojetanola, promjena vodljivosti suspenzije ne mijenja za više od 10 %, poželjno se ne mijenja za više od 6 %, poželjnije se ne mijenja za više od 3 %.
The organic-inorganic composite of claim 4, wherein the at least one substituent group and the degree of substitution is selected such that a weight percent solids at a viscosity of 1000 cps and a temperature of 150 degrees Fahrenheit is in a range from 9 percent to 43 percent. 
Zidna gips ploča prema zahtjevu 2, naznačena time, da najmanje jedna eterska skupina je hidroksietilna skupina i da ima maseni postotak krutina na viskozitetu od 1000 cps i na temperaturi od 65,6°C (150°F) u rasponu od 17 do 30%.
Pharmaceutical according to claim 5, characterized in that it is an inhalable dry powder, an inhalable aerosol with or without propellant, or an inhalable suspension or solution. 
Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 3, naznačen time, da je riječ o aerosolu za inhaliranje sa ili bez potisnog sredstva, suhom prašku za inhaliranje, suspenziji za inhaliranje ili otopini za inhaliranje.
The pharmaceutical composition for use according to claim 10, wherein: the disorder is selected from a proliferative disorder, an inflammatory disorder, an autoimmune disorder, a viral infection, an ophthalmological disorder, a neurodegenerative disorder, a disorder of abnormal tissue growth, a disorder related to food intake, allergies, and a respiratory disorder; 
Spoj za uporabu ili pripravak za uporabu u skladu sa zahtjevom 11, naznačen time što je poremećaj odabran od proliferativnog poremećaja, upalnog poremećaja, autoimunog poremećaja, virusne infekcije, oftalmološkog poremećaja, neurodegenerativnog poremećaja, poremećaja abnormalnog rasta tkiva, poremećaja povezanog s unosom hrane, alergija te respiratornog poremećaja.
An agent or composition for use according to any one of claims 3 to 9 which is to be administered with an additional therapeutic agent suitable for treating the disease, selected from a non-steroidal anti-inflammatory drug, an anti-inflammatory steroid, a gold compound, an anti-malarial drug, folic acid, cyclosporine, leflunomide, azathioprine, sulfasalazine, d-penicillamine, cyclophosphamide, mycophenoate, minocycline and chlorambucil. 
Sredstvo, ili pripravak, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 3 do 9, naznačen time što je namijenjen primjeni uz dodatno terapijsko sredstvo pogodno za liječenje bolesti, koje se bira između nesteroidnog protuupalnog lijeka, protuupalnog steroida, spoja zlata, antimalarijskog lijeka, folne kiseline, ciklosporina, leflunomida, azatioprina, sulfasalazina, D-penicilamina, ciklofosfamida, mikfenoata, minociklina 1 klorambucila.
Polysorbate 20 and polysorbate 40 should also be avoided in formulations as they are banned in certain countries. 
Polisorbat 20 1 polisorbat 40 također treba izbjegavati u pripravcima budući su
reducing a compound of formula VI with a reducing agent selected from the group consisting of borohydrides to provide a compound of formula V: 
(ii) reduciranje spoja formule VI reducensom kojeg se bira iz skupine koju čine borohidridi kako bi se dobilo spoj formule V:
The method of any one of claims 1 to 3, wherein said dissolving comprises heating the monomeric platinum pyrophosphate complex in the buffer to an elevated temperature. 
Postupak prema zahtjevu 1 ili 2, naznačen time da navedeno otapanje sadrži zagrijavanje monomernog kompleksa platina pirofosfata u puferu do povišene temperature.
The granules were mixed with microcrystalline cellulose and sodium starch glycolate (SSG) for 5 minutes. 
150 mg mikrokristalne celuloze; 60 mg natrijev škrob glikolat; i 4.5 mg magnezijev stearat.
Base elastomer supplier Compounder Masterbatch Ref. 
Ref. glavna šarža elastomera
chelating agent and solvent 
- < sredstvo za keliranje, te
The aqueous agrochemical suspension according to claim 1, wherein the suspension is a formulation and the amount of 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydrooxazole is within a range of 0.1 to 50 weight %, the amount of the at least one kind of alcohol selected from the group consisting of ethylene glycol, propylene glycol and glycerin is within a range of 0.2 to 10 weight % and the amount of the inorganic thickener is within a range of 0.1 to 5 weight % and the amount of the dispersant is within a range of 1 to 15 weight %, as opposed to the total amount of the formulation. 
Vodena agrokemijska suspenzija u skladu sa patentnim zahtjevom 1, gdje suspenzija je formulacija 1 količina 2- (2,6-difluorofenil)-4-[4-(1,1-dimetiletil)-2-etoksifeml]-4,5-dihidrooksazola je u okviru opsega od 0.1 do 50 masenih %, količina barem jedne vrste alkohola odabrane iz grupe koja se sastoji od etilen glikola, propilen glikola i glicerina je u okviru opsega od 0.2 do 10 masenih % i količina neorganskog sredstva za zgušnjavanje je u okviru opsega od 0.1 do 5 masenih % 1 količina dispergirajućeg sredstva je u okviru opsega od 1 do 15 masenih %, za razliku od ukupne količine formulacije.
continuing rinsing by recirculating water until this latter on leaving the filtration material reaches a pH value of about 7.5, 
nastavlja se s ispiranjem recirkuliranjem vode dok potonja izlazeći iz materijala za filtriranje ne dosegne PH vrijednost od otprilike 7,5, -
The method of claim 1, wherein the compound is: 
Spoj sukladno zahtjevu 1, s formulom:
The arrester according to claim 15, characterized in that the insulating body additionally comprises a strip attached to a surface of the hollow component, wherein the intermediate electrodes are embedded inside the said strip. 
Gromobran u skladu s patentnim zahtjevom 15, naznačen time što izolirajuće tijelo (1) dodatno sadrži traku pričvršćenu na površinu šuplje komponente, gdje su međuelektrode (4) uklopljene u navedenu traku.
The antibody, conjugate or pharmaceutical composition of item 19 wherein the disease or disorder is a tumor-related disease, wherein the tumor-related disease preferably is selected from the group consisting of breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. 
Protutijelo, konjugat ili farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 6 naznačeno time, što bolest ili poremećaj je bolest povezana s tumorom, pri čemu je bolest povezana s tumorom poželjno odabrana iz skupine koja se sastoji od karcinoma dojke, karcinoma želuca, karcinoma jednjaka, karcinoma pankreasa, karcinoma pluća, karcinoma jajnika, karcinoma debelog crijeva, kolorektalnog karcinoma, karcinoma jetre, karcinoma glave-vrata, karcinoma žučne vrećice i njihovih metastaza.
is selected from the group consisting of hydrogen, and methyl, ethyl and propyl, wherein said methyl, ethyl and propyl may be optionally substituted with 1, 2, or 3 fluoro substituents. 
R*"! se bira iz skupine koju čine vodik, i metil, etil i propil, gdje navedeni metil, etil i propil mogu izborno biti supstituirani s 1, 2, ili 3 fluora kao supstituentima.
The vaccine according to claims 7 or 8 or the vaccine for use according to claim 9, wherein the patient is seropositive for HSV-1, seropositive for HSV-2, seropositive for both HSV-1 and HSV-2, or seronegative for HSV-1 and HSV-2 infection. 
Cjepivo u skladu s patentnim zahtjevima 7 ili 8 ili cjepivo za uporabu u skladu s patentnim zahtjevom 9, pri čemu je pacijent seropozitivan na HSV-I1, seropozitivan na HSV-2, seropozitivan na oboje HSV-1 i HSV-2, ili seronegativan na HSV-1 i HSV-2 infekciju.
The formulation of claim 4 for use of claim 1, wherein the compound is selected from astragaloside IV, and cycloastragenol. 
Formulacija u skladu s patentnim zahtjevom 4 za upotrebu u skladu s patentnim zahtjevom 1, naznačena time što se spoj bira između astragalozida IV i cikloastragenola.
and the pharmacologically acceptable acid addition salts thereof. 
HR P20171614 T1 i njegove farmakološki prihvatljive kiselinske adicijske soli.
applying the lidding film to the peripheral flange of the container; and 
postavljanje tankog filma na obod posude; i
said second pawl rides over one of said plurality of teeth during said count stroke, and said first pawl rides over one of said plurality of teeth during said return stroke. A counter according to any one of claims 1 to 7, wherein said first and second pawls are integral with said first ring member, and said plurality of teeth are disposed on a teeth-bearing member arranged to be reciprocally moveable within the bore of said first ring member, and wherein said pawl-and-teeth mechanism is configured such that reciprocal movement of the teeth-bearing member within the bore of the first ring member causes rotational movement of the first ring member. 
Brojač kao što je navedeno u bilo kojem od zahtjeva 1 do 3, naznačeno time da su navedeni prvi i drugi zapinjači (402a, 402b) integralni s prvim prstenastim elementom (201), i navedeni pluralitet zuba (210) je postavljen na element za držanje zubi (206) smješten da bude recipročno pomičan unutar provrta navedenog prvog prstenastog elementa, i naznačeno time da je navedeni mehanizam zapinjača i zubi konfiguriran na način da recipročno kretanje elementa za držanje zubi unutar provrta prvog prstenastog elementa uzrokuje rotacijsko kretanje prvog prstenastog elementa.
A sealable container according to any preceding embodiment, wherein the thickness of the layer of adhesive is from 20 µm to 100 µm, preferably 50 µm. 
Posuda prema bilo kojem od prethodnih Zahtjeva, gdje je debljina sloja ljepila od 20 um do 100 um, a poželjno 50 um.
is hydrogen, C1 to C12 alkyl, phenyl unsubstituted or substituted by C1 to C12 alkyl or COR6 acyl group; R6 being hydrogen, C1 to C12 straight chain or branched alkyl, phenyl or benzoyl, respectively, unsubstituted or substituted by C1 to C12 alkyl, or any group leading to hydroxyl upon biological metabolization or chemical deprotection, particularly an ester, ether, acetale, carbonate, carbamate, phosphate, phosphonate, ketal, sulfate, or sulfonate, and salts thereof. 
je vodik, C1 do C12 alkil, fenil koji nije supstituiran ili je supstituiran s C1 do C12 alkilnom ili COR6 acilnom skupinom; je vodik, C1 do C12 nerazgranati ili razgranati alkil, fenil ili benzoil, koji odgovarajuće nije supstituiran ili je supstituiran s C1 do C12 alkilnom, ili bilo kojom skupinom koja se pretvara u hidroksilnu biološkim metaboliziranjem ili kemijskim uklanjanjem zaštite, gdje je navedeni spoj 4-hidroksitestosteron, ili njegove soli ili esteri.
A method for diagnosing obesity or diabetes or an increased risk for obesity or diabetes in a mammal, comprising analysis of the biological activity and/or expression of TBC1D1 in a biological sample obtained from said mammal to be diagnosed, wherein a lack or reduced expression of the gene for TBC1D1 or a lack or reduced biological activity of TBC1D1 in said mammal, when compared to a biological sample obtained from a non-diseased mammal, is indicative for an absence or a reduced risk for obesity or diabetes in said mammal. 
Metoda dijagnoze pretilosti ili dijabetesa ili povećanog rizika od pretilosti ili dijabetesa u sisavaca sastoji se od analize biološke aktivnosti i/ili ekspresije TBC1D1 u biološkom uzorku sakupljenom od sisavca kojem treba postaviti dijagnozu, pri čemu su gubitak mutacije funkcija u RAB specifičnoj GTP-azi koja aktivira TBC domenu u genu za TBC1D1, ili nedostatak ili smanjena biološka aktivnost TBC1D1 u dotičnom sisavcu indikativi za nedostatak ili smanjeni rizik od pretilosti ili dijabetesa u dotičnom sisavcu, pri čemu je navedena aktivnost TBC1D1 aktivnost RAB specifične GTP-aze koja aktivira TBC domenu.
An EZH2 inhibitor for use in the treatment of epitheloid sarcoma, wherein the EZH2 inhibitor is: or pharmaceutically acceptable salt thereof. 
EZH2 inhibitor za uporabu u liječenju epitelnog sarkoma, pri čemu je EZH2 inhibitor: